Expanded Access to Ziftomenib
Sponsor: Kura Oncology, Inc.
ClinicalTrials ID:NCT05738538
This program offers expanded access to ziftomenib for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with specific mutations or Acute Myeloid Leukemia (AML) with NPM1 mutations. The intervention involves ziftomenib monotherapy. Access is limited to the United States, and requests must be made through the provided contact information.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL), with appropriate mutations, or Acute Myeloid Leukemia (AML), with NPM1 mutations.
To request access, use Responsible Party contact information provided in this record.
Expanded access for ziftomenib is only available in the United States
Eligibility Criteria
Exclusion Criteria
Diagnosed with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Adult, ages 18+
Has exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
Meets any other pertinent medical criteria for access to the investigational drug, as established by Kura Oncology
For AML patients: Does not have KMT2A rearrangement
Get This Program In Your Inbox
You can sign up and apply your patients for this program.